Next Generation Sequencing for Wound Infection

(NGS Trial)

This trial explores whether a new test called Next Generation Sequencing (NGS) can better identify infections in patients who have undergone surgery to repair a broken bone. Infections after such surgeries can cause more pain, extend recovery time, and sometimes necessitate additional surgeries. The trial compares the effectiveness of treatment guided by both NGS and standard tests against treatment guided only by standard tests. Patients who have had surgery to fix a fracture with metal plates or screws and are now experiencing a deep infection might be suitable candidates. The goal is to improve treatment success rates and help patients recover faster with fewer complications. As a Phase 3 trial, this study represents the final step before FDA approval, offering patients a chance to contribute to a potentially groundbreaking treatment.

The trial protocol does not specify whether you need to stop taking your current medications. However, since the study involves antibiotic therapy prescribed by an Infectious Disease provider, it's possible that adjustments to your medications might be needed. Please consult with the study team for specific guidance.

Past studies have shown that Next Generation Sequencing (NGS) is a helpful tool for identifying bacteria in wound infections. Research indicates that NGS excels at detecting bacteria that are difficult to culture in a lab, which standard tests might overlook. This capability allows doctors to select the most effective antibiotic treatment more accurately.

Researchers are excited about using Next Generation Sequencing (NGS) for diagnosing wound infections because it offers a cutting-edge way to identify bacteria and other pathogens that cause infections. Unlike standard culture methods, which can miss certain microbes or take days to yield results, NGS rapidly provides comprehensive data about the entire microbial community in a wound. This means doctors can tailor antibiotic treatments more precisely and quickly, potentially leading to better patient outcomes and reduced antibiotic resistance.

Research has shown that Next Generation Sequencing (NGS), which participants in this trial may receive, can detect more types of bacteria in wound infections than standard culture tests. NGS can identify rare and difficult-to-grow bacteria, enabling doctors to select the right antibiotics more quickly. For instance, one study found that NGS detected bacteria in 51% of wound samples, offering a clearer picture of the infection. This method has shown promise for chronic wounds and burns, suggesting it could improve treatment success by reducing the need for additional surgeries. By providing a more complete view of the bacteria causing the infection, NGS can lead to quicker recovery and fewer complications. Participants in the control arm will receive standard care without the use of NGS data.¹²³⁶⁷